FILTER

LATEST INTERVIEWS

Italy
Pharma & Life Sciences

Paolo Russolo

PRESIDENT, ASCHIMFARMA – FEDERCHIMICA
Aschimfarma explains to GBR how Italian producers of APIs are well positioned to strengthen the European drug supply chain.
Mining
Canada

Mathieu Savard

PRESIDENT, OSISKO MINING
Osisko Mining updates GBR on progress at the large Windfall gold project in Québec.
United States
Pharma & Life Sciences

Eric Ostertag M.D., Ph.D.

CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.
Mining
Peru

Jaime Solano

TECHNICAL SALES DIRECTOR, TORSA
TORSA is an R&D company based in Spain with more than 20 years of experience developing solutions for different sectors, such as renewable energy, logistics and mining.
Mining
Canada

Hugh Agro

PRESIDENT & CEO, REVIVAL GOLD INC.
Revival Gold expands on progress at its Beartrack-Arnett gold project in Idaho.
Mining
Peru

Michael Cullen

MANAGING DIRECTOR - LATIN AMERICA, FTI CONSULTING
FTI Consulting speaks to GBR about the implications of Peru’s elections and COVID for the mining industry.
Mining
Peru

Roque Benavides

CHAIRMAN, BUENAVENTURA
Buenaventura comments on the political environment for mining in Peru and progress at its San Gabriel project.
Petrochemicals & Chemicals
Singapore

Alexander Donau

REGIONAL HEAD, ASIA PACIFIC, LESCHACO
Leschaco explains how the chemical industry is the mainstay of its business as it continues to increase knowledge in specialist operations.
Petrochemicals & Chemicals
Singapore

Ikunori Sakai

CEO, MCAP (MITSUI CHEMICALS ASIA PACIFIC)
Mitsui Chemicals Asia Pacific explains how it is diversifying products and expanding markets.
United States
Pharma & Life Sciences

Amit Munshi

PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL